SYRE vs VRTX
Spyre Therapeutics, Inc. vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
SYRE
Spyre Therapeutics, Inc.
67
Insufficient Data
VS
VRTX
Vertex Pharmaceuticals
66
Buy
| Metric | SYRE | VRTX |
|---|
| AI Score |
67
|
66
|
| Price |
$102.72
|
$529.70
|
| P/E Ratio |
-52.69×
|
30.58×
|
| ROE |
-21.7%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
86.0%
|
| Debt / Equity |
0.00×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
53.3
|
80.4
|
| Beta |
3.026
|
0.305
|
| Expected Upside |
—
|
+1.5%
|
AI Committee View
Current Innellis committee reasoning for SYRE versus VRTX.
SYRE leads by 1 points.
SYRE scores 67/100 (Insufficient Data) versus VRTX at 66/100 (Buy).
SYRE Committee View
100% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical
VRTX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 29.0 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- RSI at 80 is in overbought territory — Technical